Egetis Therapeutics AB (publ) (LON:0ABW)

Market Cap	130.30M
Revenue (ttm)	4.99M
Net Income (ttm)	-23.49M
Shares Out	n/a
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	94,034
Average Volume	14,026
Open	4.825
Previous Close	5.150
Day's Range	4.815 - 4.915
52-Week Range	0.306 - 0.671
Beta	1.26
RSI	35.63
Earnings Date	Feb 26, 2025

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (p...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ABW

Financial Performance

In 2023, Egetis Therapeutics AB's revenue was 57.60 million, an increase of 154.87% compared to the previous year's 22.60 million. Losses were -326.90 million, 68.7% more than in 2022.

Financial numbers in SEK